Inventor · disambiguated record
Francis Lee
Also filed as: LEE FRANCIS · LEE FRANCIS Y · LEE FRANCIS Y F · LEE FRANCIS YOUNG-IN
6 granted patents·15 pending applications·23 citations·filing 2001–2021
77Inventor score
Files withANGEX PHARMACEUTICAL INC5BRISTOL MYERS SQUIBB CO5LEE FRANCIS Y2BRISTOL MYERS SQUIBB INC1BRISTOL MYSERS SQUIBB COMPANY1
Top patents by PatentIndex Score
21 records- 0179US7312237B2Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseasesBRISTOL MYERS SQUIBB CO·Filed 2002·Granted Dec 25, 2007·8 cites·14 claims
- 0277US7037906B1Methods for modulating tumor growth and metastasisBRISTOL MYERS SQUIBB INC·Filed 2001·Granted May 2, 2006·12 cites·4 claims
- 0375US7872145B2Aziridinyl-epothilone compoundsBRISTOL MYSERS SQUIBB COMPANY·Filed 2007·Granted Jan 18, 2011·3 cites·10 claims
- 0464US2012135001A1Combination of anti-ctla4 antibody with dasatinib for the treatment of proliferative diseasesJURE-KUNKEL MARIA·Filed 2012·Application pending·0 cites
- 0558US2005159461A1Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolferative diseasesFiled 2004·Application pending·0 cites
- 0655US2006094728A1Combination of a SRC kinase inhibitor and a BCR-ABL inhibitor for the treatment of proliferative diseasesLEE FRANCIS Y·Filed 2005·Application pending·0 cites
- 0754US2006235006A1Combinations, methods and compositions for treating cancerLEE FRANCIS Y·Filed 2006·Application pending·0 cites
- 0852US2022089612A1Heterocyclic compounds as prmt5 inhibitorsANGEX PHARMACEUTICAL INC·Filed 2021·Application pending·0 cites
- 0951US2005009891A1Combination of SRC Kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseasesFiled 2004·Application pending·0 cites
- 1050US2014135367A1Use of Epothilone D in Treating Tau-Associated Diseases Including Alzheimer's DiseaseBRISTOL MYERS SQUIBB CO·Filed 2014·Application pending·0 cites
- 1149US2004209930A1Synergistic methods and compositions for treating cancerFiled 2004·Application pending·0 cites
- 1248US2005010305A1Novel bone graft compositeFiled 2004·Application pending·0 cites
- 1347US11180497B2Cyclic compounds as immunomodulating agentsANGEX PHARMACEUTICAL INC·Filed 2018·Granted Nov 23, 2021·0 cites·25 claims
- 1447US2007275904A1Conjugates of aziridinyl-epothilone analogs and pharmaceutical compositions comprising sameBRISTOL MYERS SQUIBB CO·Filed 2007·Application pending·0 cites
- 1546US2010173426A1Biomaker identifying the reactivation of stat3 after src inhibitionJOHNSON FAYE M·Filed 2007·Application pending·0 cites
- 1646US2016318928A1Tricyclic compounds as anticancer agentsBRISTOL MYERS SQUIBB CO·Filed 2014·Application pending·0 cites
- 1743US11098046B2Macrocyclic compounds as TRK kinase inhibitors and uses thereofANGEX PHARMACEUTICAL INC·Filed 2018·Granted Aug 24, 2021·0 cites·21 claims
- 1842US2013012519A1Biomarker Identifying the Reactivation of STAT3 After Src InhibitionBRISTOL MYERS SQUIBB CO·Filed 2012·Application pending·0 cites
- 1942US2009319044A1Methods and Compositions for Improving the Incorporation of Orthopaedic and Orthodontic ImplantsLEE FRANCIS YOUNG-IN·Filed 2007·Application pending·0 cites
- 2040US11358949B2Carbamate and urea compounds as multikinase inhibitorsANGEX PHARMACEUTICAL INC·Filed 2018·Granted Jun 14, 2022·0 cites·20 claims
- 2138US2020369667A1Heterocyclic compounds as prmt5 inhibitorsANGEX PHARMACEUTICAL INC·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Francis Lee files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →